This clinical overview details the latest evidence-based strategies for diagnosing and treating symptoms of benign prostatic hyperplasia in men.
Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...
Retreatment after benign prostatic hyperplasia (BPH) procedures appear lowest for men undergoing simple prostatectomy, HoLEP, ...
Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...
A regulatory decision is expected in the third quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for vibegron for the treatment of men ...
Harnessing Real-World Data and AI to Advance Research and Treatment for Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Zenflow, Inc. announced today the U.S. Food and Drug Administration (FDA) approval of the Zenflow Spring(R) Implant and Delivery System ...
Our extensive research on the Benign Prostatic Hyperplasia Treatment (2024-2032) offers valuable insights for businesses. This comprehensive report delves into emerging trends, in ...
UCHealth Longs Peak Hospital in Longmont, Colo., is using a robot-assisted procedure that incorporates AI to treat benign prostatic hyperplasia, or BPH, a common condition among older men. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results